dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 28, 2026

Crypto News Today: AlphaPepe Presale Hits $1M Raised as XRP Price Prediction Targets $13

View original at globenewswire.com
Crypto News Today: AlphaPepe Presale Hits $1M Raised as XRP Price Prediction Targets $13 MONACO, April 28, 2026 (GLOBE NEWSWIRE) -- AlphaPepe has crossed the $1 million presale milestone as Stage 14 continues at $0.01602 ahead of the Q2 2026 exchange debut…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Token delivery is instant with no vesting and no claim delay, allowing buyers to hold exposure before the exchange window opens

    60% confidence

  • XRP may still have a real long-cycle path toward $13 if adoption, ETF-related demand, and broader market conditions keep strengthening, but it is already a large-cap asset whose upside depends on outside catalysts

    60% confidence

  • Fresh institutional attention around XRP-linked ETF exposure has added another layer to the long-cycle bullish case for XRP

    60% confidence

  • AlphaPepe has crossed $1 million raised, passed 8,100 holders, pushed AlphaSwap beyond 1,000 demo users, and kept a 10/10 BlockSAFU audit in place while Stage 14 stays live at $0.01602

    60% confidence

  • AlphaSwap is a broader AI-powered swap and pre-trade intelligence layer for crypto traders, using contract screening, whale tracking, and risk signals before users enter a position

    60% confidence

  • XRP has a long-term bullish structure that keeps the $13 price scenario in play

    60% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Crypto News Today: AlphaPepe Presale Hits $1M Raised as XRP Price Prediction Targets $13: Source | Via News | fr.via.news